| Literature DB >> 28894215 |
Hyuk Soo Eun1,2, Sang Yeon Cho3, Jong Seok Joo1,2, Sun Hyung Kang1,2, Hee Seok Moon1,2, Eaum Seok Lee1,2, Seok Hyun Kim1,2, Byung Seok Lee4,5.
Abstract
Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex-derived reactive oxygen species (ROS) promote chronic liver inflammation and remodeling that can drive hepatocellular carcinoma development. The role of NOX expression in hepatocellular carcinoma (HCC) has been partially investigated; however, the clinical relevance of collective or individual NOX family member expression for HCC survival remains unclear. Here, we obtained NOX mRNA expression data for 377 HCC samples and 21 normal liver controls from the TCGA data portal and performed Kaplan-Meier survival, gene ontology functional enrichment, and gene set enrichment analyses. Although most NOX genes exhibited little change, some were significantly induced in HCC compared to that in normal controls. In addition, HCC survival analyses indicated better overall survival in patients with high NOX4 and DUOX1 expression, whereas patients with high NOX1/2/5 expression showed poor prognoses. Gene-neighbour and gene set enrichment analyses revealed that NOX1/2/5 were strongly correlated with genes associated with cancer cell survival and metastasis, whereas increased NOX4 and DUOX1 expression was associated with genes that inhibit tumour progression. On the basis of these data, NOX family gene expression analysis could be a predictor of survival and identify putative therapeutic targets in HCC.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28894215 PMCID: PMC5593889 DOI: 10.1038/s41598-017-11280-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1NOX family gene expression in liver hepatocellular carcinoma (LIHC). (A) Relative increase of NOX family mRNA expression in LIHC compared to that in normal control tissue. (B) Relative expression differences of NOX family genes in LIHC.
NADPH oxidase family of liver hepatocellular carcinoma.
| Symbol | Gene name | Aliases | Chromosome location | Fold change (Log) | Alteration (%) |
|---|---|---|---|---|---|
|
| NADPH Oxidase 1 | Mitogenic Oxidase (Pyridine Nucleotide-Dependent Superoxide-Generating) | Xq22.1 | 1.71 | 2.7 |
|
| NADPH Oxidase 2 | CYBB (Cytochrome B-245 Beta Chain), Superoxide-Generating NADPH Oxidase Heavy Chain Subunit, Heme-Binding Membrane Glycoprotein Gp91phox, Neutrophil Cytochrome B 91 kDa Polypeptide | Xp21.1 | 0.33 | 4.0 |
|
| NADPH Oxidase 3 | Mitogenic Oxidase 2, NADPH Oxidase Catalytic Subunit-Like 3 | 6q25.3 | NA | 4.0 |
|
| NADPH Oxidase 4 | Kidney Superoxide-Producing NADPH Oxidase, Kidney Oxidase-1 | 11q14.3 | 9.52 | 4.0 |
|
| NADPH Oxidase 5 | NADPH Oxidase, EF-Hand Calcium Binding Domain 5 | 15q23 | 1.07 | 4.0 |
|
| Dual Oxidase 1 | NADPH Thyroid Oxidase 1, Nicotinamide Adenine Dinucleotide Phosphate Oxidase, Flavoprotein NADPH Oxidase, Large NOX 1, Long NOX 1 | 15q21.1 | 2.28 | 5.0 |
|
| Dual Oxidase 2 | NADPH Thyroid Oxidase 2, Nicotinamide Adenine Dinucleotide Phosphate Oxidase | 15q21.1 | 1.27 | 3.0 |
Clinicopathological information of the liver hepatocellular carcinoma patients.
| Feature | Total (%) |
|---|---|
|
| 377 (100.0) |
|
| 377 (100.0) |
| Female | 122 |
| Male | 255 |
|
| 377 (100.0) |
| ≤ 60 years | 180 |
| > 60 years | 196 |
|
| 1 |
|
| 377 (100.0) |
| Stage I | 175 |
| Stage II | 87 |
| Stage III | 86 |
| Stage IV | 5 |
| NA | 24 |
|
| 377 (100.0) |
| Grade 1 | 55 |
| Grade 2 | 180 |
| Grade 3 | 124 |
| Grade 4 | 13 |
| NA | 5 |
|
| 377 (100.0) |
| Alive | 245 |
| Dead | 132 |
|
| 377 (100.0) |
| A | 223 |
| B | 21 |
| C | 1 |
| NA | 132 |
|
| 377 (100.0) |
| Hepatocholangiocarcinoma | 7 |
| Hepatocellular carcinoma | 367 |
| Fibrolamellar carcinoma | 3 |
|
| 377 (100.0) |
| Mild | 101 |
| Severe | 19 |
| None | 119 |
| NA | 138 |
|
| 377 (100.0) |
| 0 – no fibrosis | 76 |
| 1,2 – portal fibrosis | 31 |
| 3,4 – fibrous septa | 30 |
| 5 – nodular formation and incomplete cirrhosis | 9 |
| 6 – established cirrhosis | 72 |
| NA | 159 |
|
| 377 (100.0) |
| Yes | 76 |
| No | 234 |
| NA | 67 |
|
| 377 (100.0) |
| > 3.5 | 217 |
| ≤ 3.5 | 86 |
| NA | 74 |
|
| 377 (100.0) |
| ≤ 20 | 152 |
| > 20 | 132 |
| NA | 93 |
|
| |
| Hepatitis B | 105 |
| Hepatitis C | 51 |
| Hepatitis B + C | 7 |
| Alcohol consumption | 118 |
| Non-alcoholic fatty liver disease | 18 |
Figure 2Survival analysis of NOX family genes in LIHC. Kaplan-Meier analysis of the association between mRNA expression of NOX family and overall survival of the patients. (A) Cumulative overall survival curve of the patients with high and low expression of NOX3, NOX4 and DUOX1 and 2 (B). Cumulative overall survival curve of the patients with high and low expression of NOX1, NOX2, and NOX5. P values were determined by Fisher’s exact test.
Figure 3GSEA results for tumours with high NOX 1-5 expression. Representative GSEA data with p values for (A) NOX1, (B) NOX2, (C) NOX3, (D) NOX4, and (E) NOX5 are shown.
Figure 4GSEA results for tumours with high DUOX1/2 expression. Representative GSEA data with p values for (A) DUOX1 and (B) DUOX2 are shown.